Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 10Terminated 8Recruiting 4Active not recruiting 4Withdrawn 2Suspended 1Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Colorectal Neoplasms 37Recurrence 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 28Lymphoma 26Pancreatic Neoplasms 25Melanoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Leukemia 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Epstein-Barr Virus Infections × Clear all
NCT06429800 2025-04-24

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Atara Biotherapeutics

Phase 1 Withdrawn

Lupus Erythematosus, Systemic, Lupus Nephritis, Epstein-Barr Virus Infections

NCT02229981 2017-12-07

ABC-102

RedHill Biopharma Limited

Phase 1/2 Withdrawn
LymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡